Cefpodoxime + Clavulanic Acid
Upper respiratory tract infection: Pharyngitis, Tonsillitis.
Lower respiratory tract infection: Acute exacerbations of chronic bronchitis, Acute community acquired pneumonia.
Skin and Soft Tissue Infections.
Urinary tract infection: Cystitis, Uncomplicated urinary tract infections.
General gonorrhea and rectal gonococcal infections.
Cefpodoxime-Clavulanic acid preparation prevents the resistance to Cefpodoxime that may increase with continuous usage of the drug. It has shown effectiveness against multiple Gram-positive and Gram-negative bacteria and is generally well tolerated.
Dosage & Administration
Uncomplicated urinary tract infections: 100 mg 12 hourly for 7 days
Complicated urinary tract infections: 200 mg 12 hourly for7 days
Acute community acquired pneumonia: 200 mg 12 hourly for 14 days
Acute bacterial exacerbations of chronic bronchitis: 200 mg 12 hourly for 10 days
Uncomplicated gonorrhea and rectal gonococcal infections: single dose
Skin and skin structure infections: 200-400 mg 12 hourly for 7 to 14 days
Acute maxillary sinusitis: 200 mg 12 hourly for 10 days
Enteric fever: 200 mg 12 hourly for 7 to 14 days
Nephrotoxic drugs: Close monitoring of renal function is advised when Cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.
Pregnancy & Lactation
Use in Special Population
Patients with cirrhosis: Cefpodoxime pharmacokinetics in cirrhotic patients (with or without ascites) is similar to those in healthy subjects. Dose adjustment is not necessary in this population.